

## REGULATION OF Na<sup>+</sup>/H<sup>+</sup> ANTIPORTER IN TROUT RED BLOOD CELLS

MURIELLE MALAPERT, HELENE GUIZOUARN, BRUNO FIEVET, ROLAND JAHNS,  
FEDERICO GARCIA-ROMEU, RENE MOTAIS AND FRANCK BORGESE\*

Laboratoire Jean Maetz, URA 1855, Département de Biologie Cellulaire et Moléculaire CEA, BP 68,  
06230 Villefranche-sur-Mer, France

### Summary

The trout red blood cell Na<sup>+</sup>/H<sup>+</sup> antiporter ( $\beta$ NHE) displays two interesting properties: it is the only NHE known to be activated by cyclic AMP, and the activation process is followed by a desensitisation of the transport system itself.

Cloning and expression of  $\beta$ NHE have provided significant information about Na<sup>+</sup>/H<sup>+</sup> activation, in particular that activation by cyclic AMP is directly dependent upon the presence of two protein kinase A consensus sites in the cytoplasmic tail of the antiporter. Expression of  $\beta$ NHE in fibroblasts demonstrates that the protein kinase A (PKA) and protein kinase C (PKC) activation pathways are independent and do not converge on a common kinase. Moreover, the hydrophilic C-terminal fragment is essential to the mediation of the various hormonal responses. NHE1 (the human ubiquitous isoform) is not activated by cyclic AMP, but a 'NHE1 transmembrane domain/ $\beta$ NHE cytoplasmic domain' chimera is fully activated by cyclic AMP.

In red cells, activation of  $\beta$ NHE is the result of

phosphorylation by PKA of at least two independent sites. Desensitisation, inhibited by the phosphatase inhibitor okadaic acid, may consist of the dephosphorylation of one of these two sites. Furthermore, Calyculin A (CIA), another specific protein phosphatase inhibitor, induces in unstimulated cells a Na<sup>+</sup>/H<sup>+</sup> exchange activity whose exchange properties are very different from those of the adrenergically stimulated antiporter. It is suggested that CIA may be able to revive 'sequestered' antiporters.

We propose that the molecular events underlying  $\beta$ NHE desensitisation could be similar to those involved in rhodopsin desensitisation. Antibodies were generated against trout red cell arrestin in order to analyse the binding of arrestin to the activated exchanger. Recombinant trout arrestin was produced in a protease-deficient strain of *Escherichia coli* and its functionality tested in a reconstituted rhodopsin assay.

Key words: Na<sup>+</sup>/H<sup>+</sup> exchanger, protein kinase A, protein kinase C, protein phosphatase, desensitisation, arrestin, erythrocyte.

### Introduction

The Na<sup>+</sup>/H<sup>+</sup> Exchanger (NHE) is a plasma membrane transport protein found in a wide range of biological systems. The stoichiometry of the exchange is 1 H<sup>+</sup> to 1 Na<sup>+</sup>, and thus the exchanger is electrically neutral. The Na<sup>+</sup>/H<sup>+</sup> exchange process is driven by the combined chemical gradients of Na<sup>+</sup> and H<sup>+</sup>; under normal physiological conditions, there is a large driving force favouring net entry of Na<sup>+</sup> in exchange for internal H<sup>+</sup>. The antiporter can also mediate Li<sup>+</sup>/H<sup>+</sup> exchange as well as self exchange for Na<sup>+</sup> and Li<sup>+</sup> (Na<sup>+</sup>/Li<sup>+</sup>). Protons play a key role in the regulation of the antiporter. Extracellular protons can inhibit the exchange by competing with external Na<sup>+</sup>. Conversely, intracellular protons activate the exchange with kinetic parameters in accordance with an allosteric model suggesting the presence of two distinct internal proton-binding sites interacting cooperatively. This behaviour can be explained by the probable existence of a second cytoplasmic H<sup>+</sup> binding site termed a 'modifier'. The binding of a proton would increase the affinity of the transporter site for protons and therefore increase the rate of exchange. The consequence of this phenomenon is that, despite favourable conditions, the Na<sup>+</sup>/H<sup>+</sup>

exchanger is normally quiescent but rapidly becomes activated as soon as the acidity of the cytoplasm increases. The exchanger thus reacts to cell acidification by adjusting the internal pH (pHi) to a 'set point' exactly as does a 'pH stat'. The main function of the antiporter is thus to regulate intracellular pH and to protect the cell against intracellular acidification. In addition, NHE can be activated at a physiological pHi by various stimuli (growth factors, hormones, phorbol esters and hyperosmotic shock) which act by increasing the proton affinity of the transport site. Thus, after such stimulation, the dependence of the antiport activity on pHi is shifted into a more alkaline range. Since the 'set point' is shifted from its previous pH, Na<sup>+</sup>/H<sup>+</sup> exchange helps to maintain pHi at its new value (for reviews, see Clark and Limbird, 1991; Yun *et al.* 1995).

NHE is involved in various functions including pH homeostasis, volume regulation, cell proliferation and transcellular Na<sup>+</sup> absorption. The existence of several isoforms of the exchanger had been predicted (1) by the broad range of physiological functions in which it is involved, (2) by the different types of protein kinase regulation in different cell

\*Author for correspondence (e-mail: borge@ccrv.obs-vlfr.fr).

types and (3) by the variable sensitivity of the exchanger to the diuretic amiloride. NHE is inhibited by amiloride and its derivatives, but the degree of inhibition varies from cell type to cell type and among different plasma membrane domains (apical *versus* basolateral) (for a review, see Clark and Limbird, 1991). The first Na<sup>+</sup>/H<sup>+</sup> exchanger was cloned by Sardet *et al.* (1989) and called NHE1. The cloning of NHE1 greatly facilitated the isolation of different isoforms, and four new isoforms have now been cloned: the trout red cell antiporter βNHE (Borgese *et al.* 1992) and three further mammalian subtypes: NHE2, NHE3 and NHE4 (Orlowski *et al.* 1992; Collins *et al.* 1993; Tse *et al.* 1993). NHE2 and NHE3 are expressed in kidney, colon, small intestine and stomach (Orlowski *et al.* 1992; Wang *et al.* 1993; Tse *et al.* 1993). They represent the apically expressed NHE isoforms described in epithelia, NHE1 being expressed on the basolateral membrane. βNHE, present in the membrane of trout red cells, represents an interesting isoform of the NHE family which possesses the basic properties described for other cell types but also shows certain specific characteristics: (1) it does not regulate intracellular pH; (2) it is activated by adrenergic agonists; and (3) its activation is rapidly followed by its desensitisation (Motais *et al.* 1990). This antiporter is activated *in vivo* when the fish finds itself in hypoxic water (Fiévet *et al.* 1987, 1988; Thomas *et al.* 1988), thus promoting intracellular alkalization which increases, *via* a Bohr effect, the affinity of haemoglobin for oxygen (Claireaux *et al.* 1988; Cossins and Richardson, 1985; Nikinmaa, 1982).

In red cells, the antiporter does not regulate intracellular pH. Anions and protons are passively distributed across the red cell membrane according to a Donnan equilibrium:  $[Cl^-]_i/[Cl^-]_o = [HCO_3^-]_i/[HCO_3^-]_o = [H^+]_o/[H^+]_i$ . When the acid–base status is disturbed, this equilibrium is modified by the redistribution of anions (HCO<sub>3</sub><sup>-</sup> and Cl<sup>-</sup>) by the anionic exchanger (band 3), which explains the linear relationship between erythrocyte pH and extracellular pH. βNHE remains inactivated even when the intracellular pH drops to 6.3, a value outside the normal physiological pH<sub>i</sub> range; below this pH, it becomes active, indicating that the set point in red blood cells (RBCs) is approximately pH 6.5 (Motais *et al.* 1990). At a physiological pH, it has previously been demonstrated, *in vitro* and later *in vivo*, that this antiporter is activated by catecholamines which, by increasing intracellular cyclic AMP concentration, stimulate PKA (for a review, see Fiévet and Motais, 1991). Addition of catecholamines to resting RBCs strongly activates the antiporter: the Na<sup>+</sup> influx increases enormously (100-fold), reaching its maximal value within 2–3 min and then, despite the continuing presence of the activator, the Na<sup>+</sup>/H<sup>+</sup> exchange declines rapidly as a result of a desensitisation of the transport system (Garcia-Romeu *et al.* 1988). The phorbol ester PMA (phorbol myristate acetate), a protein kinase C activator, also stimulates βNHE but the activity is only 25% of that induced by catecholamines (Motais *et al.* 1990). It was intriguing to speculate about this dual activation pathway. Do protein kinase A and protein kinase C act through an ancillary protein or does each kinase promote a separate

phosphorylation of a distinct part of the protein? Results obtained from transfected Na<sup>+</sup>/H<sup>+</sup> (see below) will provide the answer. In this report, we will give a resumé of the major results contributing to the understanding of the regulation of βNHE, with special emphasis on the phenomenon of desensitisation.

### Molecular identification of βNHE

βNHE was cloned from trout cephalic kidney, the fish haematopoietic tissue, and later from circulating erythrocytes (Borgese *et al.* 1992). βNHE is a protein of 759 amino acids (predicted size 85 kDa), with a hydrophathy profile very similar to those of all NHEs (Fig. 1). The antiporter consists of two distinct domains: an amphipathic N-terminal domain (467 amino acids) which contains 12 membrane-spanning segments and a very highly hydrophilic C-terminal domain corresponding to a large cytoplasmic region (292 amino acids). Fig. 2 shows the homologies between NHE isoforms. The transmembrane domains are the most conserved regions. It should be noted that the transmembrane Va and Vb helices are the most constant regions, exhibiting 95% homology, suggesting that this region is essential to exchange activity (Fafournoux *et al.* 1994). βNHE, although not a mammalian antiporter, is the nearest isoform to NHE1, suggesting that βNHE may be a basolateral isoform. Moreover βNHE, like NHE1, is an N-glycosylated protein (Fig. 3), a characteristic not shown by the 'apical' isoform NHE3 (Counillon *et al.* 1994). The exact glycosylation site (Asn49 or Asn337) has not yet been defined; however, results obtained with NHE1 indicate that glycosylation is at the first site (Asn49).

### Regulation of transfected βNHE

Functional expression of βNHE was carried out in fibroblast cell line PS120, which lacks an endogenous Na<sup>+</sup>/H<sup>+</sup> exchange. In PS120 cells, there was no effect of cyclic AMP on the activity of any exchanger other than βNHE (Levine *et al.* 1993). Stably expressed βNHE is stimulated by cyclic AMP or catecholamines (Borgese *et al.* 1992). The C-terminal domain of βNHE contains two typical consensus sites for protein kinase A (Arg-Arg-X-Ser) that are very close together (Ser641 and Ser648). There are no such consensus sites on NHE1, which is not activated by cyclic AMP. PKA consensus sites are necessary for the complete stimulation of the antiporter. A truncated βNHE exchanger with the last 200 amino acids deleted (βNHEΔ559) is no longer activated by cyclic AMP. Deletion of the distal C-terminal domain did not reduce the ability of NHE to catalyse Na<sup>+</sup>/H<sup>+</sup> exchange and preserved the characteristics of the H<sup>+</sup> modifier site (Wakabayashi *et al.* 1992). Point mutations of Ser641 and Ser648 were made (serine changed to glycine) to examine the relative involvement of these serines in the activation mechanism. Mutation of either Ser641 or Ser648 causes a 60% decrease in the ability of cyclic AMP to activate the exchanger. The two serines are involved in the activation pathway to the same degree. The simultaneous removal of the two consensus sites did not totally abolish the




Fig. 1. Primary amino acid sequence and deduced topological model of  $\beta$ NHE. The arrow shows the putative N-glycosylation consensus site (Asn49). The two protein kinase A (PKA) consensus sites are underlined, and the position of the membrane is shaded.  $\Delta$ 559 shows the point where the deletion was performed to obtain the deleted antiporter  $\beta$ NHE $\Delta$ 559.

activity, but reduced it to 28% of the control value. Using selective deletion mutations, we have shown that the element triggering this residual activity was located in fragment 559–661 of the cytoplasmic tail. As was to be expected, PKC activation of  $\beta$ NHE was unaffected by removal of PKA consensus sites. A significant observation, however, was that the truncated antiporter  $\beta$ NHE $\Delta$ 559 was still activated by phorbol esters and thrombin. Obviously, PKC determinant elements are not co-located in region 559–759 of  $\beta$ NHE. It is clear that the two protein kinases stimulate exchange activity by acting on different parts of  $\beta$ NHE.

We have seen that region 559–759 contains all the determinants for cyclic AMP activation. Does this region determine the hormonal behaviour of the antiporter? The

	$\beta$ NHE	NHE1	NHE2	NHE3	NHE4
$\beta$ NHE	100 %	74 %	52 %	51 %	50 %
NHE1	49 %	100 %	49 %	48 %	48 %
NHE2	37 %	36 %	100 %	47 %	57 %
NHE3	28 %	33 %	33 %	100 %	47 %
NHE4	35 %	34 %	44 %	31 %	100 %

Fig. 2. Amino acid sequence homology between  $\text{Na}^+/\text{H}^+$  exchanger isoforms. Amino acid alignments were performed on transmembrane and cytoplasmic regions independently. The homology levels for each region are shown in the two distinct portions of the figure. The shaded part corresponds to the transmembrane-restricted regions. NHE sequences are from Orlowski *et al.* (1992) and Collins *et al.* (1993).




Fig. 3. Immunoblot showing the effect of deglycosylation on the electrophoretic mobility of  $\beta$ NHE. Membrane preparations of PS120 and PS120-expressing  $\beta$ NHE cells (50  $\mu$ g) were submitted to digestion by N-glycosidase F (1000 units) prior to SDS-PAGE electrophoresis and western blotting. Western blotting was carried out using a purified antipeptide raised against the last 15 C-terminal amino acids.

cytoplasmic part of  $\beta$ NHE (containing the two consensus sites) was grafted onto the transmembrane domain of NHE1 and the resulting chimera was called 'mermaid'. In PS120 cells, NHE1 and  $\beta$ NHE respond differently to cyclic AMP, NHE1 activity being unaffected by an increase in intracellular cyclic AMP concentration. However, cyclic AMP activates 'mermaid' just as it activates  $\beta$ NHE (Borgese *et al.* 1994). This result clearly demonstrates that the C-terminal domain of  $\beta$ NHE can confer cyclic-AMP-dependent activation on NHE1. The transmembrane domain is sufficiently homologous to  $\beta$ NHE (74%) to allow interaction of the  $\beta$ NHE cytosolic regulator domain with the NHE1 transporting domain. Cyclic AMP stimulation of 'mermaid' is dependent on the presence of PKA consensus sites, suggesting that activation is probably due to phosphorylation of the antiporter. The importance of phosphorylation in the activation of the different NHE isoforms remains unclear. It has been reported that the mitogenic activation of NHE1 is accompanied by an increase in phosphorylation (Sardet *et al.* 1990, 1991). Subsequently, it has been shown that thrombin and epidermal growth factor (EGF) activate the antiporter by phosphorylating a set of common sites. The two independent mechanisms (receptor-tyrosine-kinase- and PKC-dependent pathways) could converge on a common activating protein. The nature of this regulatory protein is still unknown, but mitogen-activated protein kinase (MAP kinase) would be a good candidate (Pagès *et al.* 1993). Nevertheless, several results, based on partial deletion of NHE1, strongly suggest that phosphorylation alone cannot fully explain the activating process (for a review, see Bianchini and Pouyssegur, 1996). It has been proposed that a regulatory protein, itself a target for a kinase(s), may control NHE1 activation through a direct interaction with the cytoplasmic tail (Wakabayashi *et al.* 1994).

The effects of cyclic AMP on the different NHE isoforms

vary greatly depending on the cell line in which they are expressed. NHE3, which possesses three PKA consensus sites in the cytoplasmic domain, is insensitive to cyclic AMP when expressed in PS120 cells, but has its activity inhibited in opossum kidney (OK) and AP-1 cell lines (Helme-Kolbe *et al.* 1990; Azarani *et al.* 1995; Moe *et al.* 1995). Phosphorylation of the cytoplasmic domain could explain PKA inhibition in OK cells (Moe *et al.* 1995). More intriguing results are obtained with NHE1, which is insensitive to cyclic AMP in PS120 cells but is stimulated when expressed in AP-1 cells (Kandasamy *et al.* 1995). Since NHE1 has no PKA consensus site, it is necessary to assume the presence of a cyclic AMP/PKA regulator protein interacting with NHE1. This protein would be tissue-specific and not expressed in PS120 cells.

In conclusion, the effects of cyclic AMP on NHEs are variable but can be partly explained by the presence of PKA consensus sites. The results obtained with  $\beta$ NHE and 'mermaid' clearly support this proposition. Nevertheless, several additional factors, as yet not clearly defined, operating independently of PKA sites but themselves regulated by kinases, would explain some of the cell type variations. Further studies, including the correct localisation of NHE phosphorylation sites, must be undertaken to elucidate the role of phosphorylation in NHE activation. The role of the PKA consensus sequences observed in NHEs physiologically inhibited by cyclic AMP (NHE2 and NHE3) remains to be determined. Stable expression of  $\beta$ NHE in OK cells could provide new clues to the understanding of cyclic AMP regulation of NHEs.

#### Desensitisation of red blood cell $\text{Na}^+/\text{H}^+$ antiporters

In trout red cells, as discussed above, the  $\text{Na}^+/\text{H}^+$  exchanger is inactive at physiological pH and remains inactive when the cells become acidic. Thus, unlike other NHE isoforms,  $\beta$ NHE in the membrane is in a non-functional state. However,  $\beta$ NHE can be strongly and rapidly activated (Fig. 4) by addition of  $\beta$ -adrenergic agonists or cyclic AMP analogues to the suspending medium. These stimuli, *via* a phosphorylation mediated by a cyclic-AMP-dependent protein kinase (PKA), shift the antiport from a non-functional to a functional conformation by changing the characteristics of the internal  $\text{H}^+$  modifier site and the  $V_{\text{max}}$  of the exchange (Guizouarn *et al.* 1993). This cyclic-AMP-dependent phosphorylation responsible for  $\beta$ NHE activation is controlled by an okadaic acid (OA)-insensitive phosphatase (Guizouarn *et al.* 1993). Note that, conversely, the activation of NHE1 is controlled by an OA-sensitive phosphorylation (Sardet *et al.* 1991). As illustrated in Fig. 4, when the non-functional antiporter has been forced into the activated state by PKA-dependent phosphorylation,  $\text{Na}^+$  influx reaches a maximal value 2 min after adrenergic stimulation and then falls abruptly and exponentially towards the unstimulated value ( $t_{1/2}=30$  min). This decrease in  $\text{Na}^+/\text{H}^+$  activity does not reflect a desensitisation of elements involved in the transmission of the hormonal signal (e.g.  $\beta$ -adrenergic receptor and/or G-protein); indeed, it also occurs when an exogenous cyclic AMP analogue






Fig. 4. Time-dependent changes of Na<sup>+</sup> influx in red blood cells after  $\beta$ -adrenergic stimulation. Redrawn from Garcia-Romeu *et al.* (1988).

is used to stimulate Na<sup>+</sup>/H<sup>+</sup> antiport directly, thus bypassing receptor-mediated phenomena at the cell surface (Garcia-Romeu *et al.* 1988). This decline in activity also does not reflect a simple activation/deactivation transition of the antiporter, but a transition from an active to a refractory state.  $\beta$ NHE can no longer be immediately reactivated by a fresh challenge with catecholamine or cyclic AMP. Several hours without stimulation are necessary for the exchanger to recover its ability to respond to cyclic AMP or catecholamines (Guizouarn *et al.* 1993). The decline in activity thus reflects a desensitisation of the transport system itself (Garcia-Romeu *et al.* 1988). This  $\beta$ NHE desensitisation is blocked and reversed by OA, indicating control by an OA-sensitive phosphatase of the phosphorylation level of a site critical for the desensitisation process. Phosphorylation of this site is also mediated by a cyclic-AMP-dependent protein kinase (Guizouarn *et al.* 1993).

In conclusion, the activation of  $\beta$ NHE would result from the phosphorylation by PKA of at least two different sites, one being insensitive to OA, switching the antiporter on, and the other sensitive to this inhibitor, being necessary to maintain the antiporter in a 'transporting' state. Desensitisation would be due to the dephosphorylation of the OA-sensitive site by a protein phosphatase 1 (PP1) (Guizouarn *et al.* 1993, 1995). Experiments designed to evaluate the phosphorylation state of the antiporter, immunoprecipitated from red cells, at different times after stimulation are in progress.

The refractory state could correspond to a recycling of the desensitised transporters in the membrane, and some data obtained using Calyculin A (CIA) support this possibility (Guizouarn *et al.* 1995). CIA is a phosphatase inhibitor that is 10–100 times more potent than OA as a PP1 inhibitor. It is also 10 times more potent than OA in blocking desensitisation. Furthermore, CIA, unlike OA, induces a large Na<sup>+</sup>/H<sup>+</sup> exchange activity in unstimulated cells. The characteristics of CIA-induced and PKA-induced Na<sup>+</sup>/H<sup>+</sup> exchange are very different. Moreover, simultaneous addition of maximal concentrations of CIA and catecholamine produces an additive stimulation of the

Na<sup>+</sup>/H<sup>+</sup> exchange consistent with the interpretation that these agents act on two distinct pools of exchangers (Guizouarn *et al.* 1995). Since cloning of  $\beta$ NHE showed that only one isoform is present in circulating red cells, it seems likely that CIA is able to unmask antiporters normally inaccessible to activation by PKA or PKC. A simple explanation is that CIA activation corresponds to the recruitment of the refractory sequestered antiporters *via* an effect on the cytoskeleton. Indeed, CIA is known to induce large modifications of microtubules and microfilaments (Gurland and Gundersen, 1993; Chartier *et al.* 1996). The use of  $\beta$ NHE antibodies in microscopic studies will be essential to evaluate the validity of this interpretation.

#### Is arrestin involved in Na<sup>+</sup>/H<sup>+</sup> desensitisation?

Our knowledge of the mechanisms implicated in the desensitisation process mainly derives from the study of two G-protein-coupled receptor systems: the light receptor or rhodopsin and the  $\beta$ -adrenergic receptor. In both systems, a cytosolic protein termed arrestin plays a key role in the desensitisation process. Arrestin is a 48 kDa protein which binds to activated phosphorylated rhodopsin or  $\beta$ -receptors ( $\beta$ -arrestin) (Wilden *et al.* 1986; Shinohara *et al.* 1987; Lohse *et al.* 1990, 1992). This binding precludes receptor–G-protein interaction and thus interrupts the activation process. To investigate a possible role of arrestin in the desensitisation of the trout red cell antiporter, we have used immunochemical techniques to demonstrate the presence of an arrestin-like protein in nucleated red cells (Mirshahi *et al.* 1989). Prior to this demonstration, arrestin was assumed to be localised exclusively in photosensitive cells. This red cell arrestin binds to photoactivated rhodopsin just as the retinal arrestin does, supporting its possible involvement in some undefined desensitisation process (Scheuring *et al.* 1990). To investigate the physiological role of arrestin in red cells, several approaches have been used. First, molecular cloning demonstrates that three different isoforms of arrestin coexist in circulating trout red blood cells: TRCarr1, TRCarr2 and TRCarr3 (Jahns *et al.* 1996), TRCarr standing for **T**rou**T** **R**ed **C**ell **a**rrestin. The three TRCarrs exhibit very high homology with each other (97%) and are highly homologous to the other vertebrate arrestins cloned so far: retinal arrestin (Wilden *et al.* 1986), retinal cone (C) arrestin (76%; Shinohara *et al.* 1987),  $\beta$ -arrestin 1 (82%; Lohse *et al.* 1990; Parruti *et al.* 1993) and  $\beta$ -arrestin 2 (52%; Stern-Marr *et al.* 1993; Attramadal *et al.* 1992; Rapoport *et al.* 1992). Two polyclonal antibodies were then generated by a protein fusion technique, one raised against the N-terminal part of the protein and the other against the C-terminal part. These antibodies are able to immunoprecipitate TRCarr not only from the cytoplasm but also from the particulate (membrane) fraction of RBCs (Fig. 5). The variation of arrestin bound to the membrane was examined as a function of time after catecholamine stimulation. No significant modification of arrestin distribution during the desensitisation process was detected (Jahns *et al.* 1996). However, the immunoprecipitation protocol used is not sufficiently sensitive to exclude the




Fig. 5. Immunoblot of arrestin immunoprecipitated from the cytosol (Cyto) and membranes (Mb) of trout red cells. Immunoprecipitation and subsequent western blotting were performed using an anti-TRCarr antibody as described by Jahns *et al.* (1996).

possibility that only a few arrestins from the cytoplasmic pool are implicated in the regulation of the  $\text{Na}^+/\text{H}^+$  antiporter. For a modified experimental approach (*in vitro* interaction), a large amount of TRCarr was necessary, but previous isolation of native arrestin from RBCs had been found to yield denatured and aggregated protein. We succeeded in producing TRCarr using a recombinant expression strategy with bacterial hosts: the pET expression system was used to produce recombinant TRCarr (rTRCarr) in the *E. coli* strain BL-21 (Jahns *et al.* 1996). rTRCarr was engineered with a histidine tag (6His) at the C-terminal part of the protein. This tag was shown to allow protein purification on a  $\text{Ni}^{2+}$  affinity-chromatography column (Hochuli *et al.* 1987). rTRCarr protein can be labelled by either the N- or the C-terminal-specific anti-TRCarr antibodies, proving the integrity of the purified expressed protein (Jahns *et al.* 1996). The functional integrity of the recombinant protein was tested in a reconstituted rhodopsin assay. Fig. 6 shows that rTRCarr binds to phosphorylated and light-activated rhodopsin from bovine retinal rod outer segment, but that there was also an additional significant binding of rTRCarr to the non-photoactivated rhodopsin. The binding of rTRCarr to the light-activated rhodopsin, however, was much more pronounced than that to the non-photoactivated rhodopsin. Moreover, addition to the samples of  $1 \text{ mg ml}^{-1}$  heparin, which has previously been shown to inhibit arrestin–rhodopsin interactions (Gurevich *et al.* 1994), completely blocked the binding of rTRCarr to rhodopsin, even after photoactivation. This indicates that




Fig. 6. Immunoblot of rhodopsin-bound rTRCarr. rTRCarr was assayed for activity in a reconstituted bovine rhodopsin system. Rod outer segment (ROS) disc membranes were prepared from fresh bovine retina. The binding of rTRCarr to bovine rhodopsin was assayed in the presence of  $3 \text{ mmol l}^{-1}$  ATP and  $0.1 \text{ mmol l}^{-1}$  GTP $\gamma$ S (to keep transducin in the active form) by mixing, in the dark, the ROS preparation, containing rhodopsin and membrane-bound rhodopsin kinase, with rTRCarr. The mixtures were either kept in the dark or exposed to light for 1 h at  $30^\circ\text{C}$ . The samples were shaken overnight at  $4^\circ\text{C}$  to remove bound arrestins from the rhodopsin and then centrifuged. The arrestin-containing supernatants were loaded on 11% SDS–polyacrylamide gels and tested by western blot as by described by Jahns *et al.* (1996). +Heparin, the same experiment was performed in the presence of  $1 \text{ mg ml}^{-1}$  heparin, which inhibits the binding of arrestin to rhodopsin. Redrawn from Jahns *et al.* (1996).

rTRCarr is a suitable tool for further investigation of the functional role of TRCarr in the trout erythrocyte and may also be helpful in the identification of its appropriate target in these cells.

## References

- ATTRAMADAL, H., ARRIZA, J. L., AOKI, C., DAWSON, T. M., CODINA, J., KWATRA, M. M., SNYDER, S. H., CARON, M. G. AND LEFKOWITZ, R. J. (1992).  $\beta$ -Arrestin2, a novel member of the arrestin/ $\beta$ -arrestin gene family. *J. biol. Chem.* **267**, 17882–17890.
- AZARANI, A., GOLTZMAN, D. AND ORLOWSKI, J. (1995). Parathyroid hormone and parathyroid hormone-related peptide inhibit the apical  $\text{Na}^+/\text{H}^+$  exchanger NHE-3 isoform in renal cells (OK) via a dual signaling cascade involving protein kinase A and C. *J. biol. Chem.* **34**, 20004–20010.
- BIANCHINI, L. AND POUYSSÉUR, J. (1996). Regulation of the  $\text{Na}^+/\text{H}^+$  exchanger isoform NHE1: Role of phosphorylation. *Kidney Int.* **49**, 1038–1041.
- BORGESE, F., MALAPERT, M., FIÉVET, B., POUYSSÉUR, J. AND MOTAIS, R. (1994). The cytoplasmic domain of the  $\text{Na}^+/\text{H}^+$  exchangers (NHEs) dictates the nature of the hormonal response: behavior of a chimeric human NHE1/trout  $\beta$ NHE antiporter. *Proc. natn. Acad. Sci. U.S.A.* **91**, 5431–5435.
- BORGESE, F., SARDET, C., CAPPADORO, M., POUYSSÉUR, J. AND MOTAIS, R. (1992). Cloning and expression of a cyclic AMP-

- activated Na<sup>+</sup>/H<sup>+</sup> exchanger: Evidence that cytoplasmic domain mediates hormonal regulation. *Proc. natn. Acad. Sci. U.S.A.* **89**, 6765–6769.
- CHARTIER, L., RANKIN, L. L., ALLEN, R. E., KATO, Y., Fusetani, N., KARAKI, H., WATABE, S. AND HARTSHORNE, D. J. (1996). Caliculin A increases the level of protein phosphorylation and changes the shape of 3T3 fibroblasts. *Cell. Motil. Cytoskeleton* **18**, 26–40.
- CLAIREAUX, G., THOMAS, S., FIÉVET, B. AND MOTAIS, R. (1988). Adaptive respiratory responses of trout to acute hypoxia. II. Blood oxygen carrying properties during hypoxia. *Respir. Physiol.* **74**, 91–98.
- CLARK, J. D. AND LIMBIRD, L. E. (1991). Na<sup>+</sup>-H<sup>+</sup> exchanger subtypes: a predictive review. *Am. J. Physiol.* **261**, C945–C953.
- COLLINS, J. F., HONDA, T., KNOBEL, S., BULUS, N. M., CONARY, J., DUBOIS, R. AND GHISHAN, F. K. (1993). Molecular cloning, sequencing, tissue distribution and functional expression of a Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE-2). *Proc. natn. Acad. Sci. U.S.A.* **90**, 3938–3942.
- COSSINS, A. R. AND RICHARDSON, P. A. (1985). Adrenalin-induced Na<sup>+</sup>/H<sup>+</sup> exchange in trout erythrocytes and its effects upon oxygen-carrying capacity. *J. exp. Biol.* **118**, 229–246.
- COUNILLON, L., POUYSSÉGUR, J. AND REITHMEIER, R. A. F. (1994). The Na<sup>+</sup>/H<sup>+</sup> exchanger NHE-1 possesses N- and O- linked glycosylation restricted to the first N-terminal extracellular domain. *Biochemistry, N.Y.* **33**, 10463–10469.
- FAFOURNOUX, P., NOEL, J. AND POUYSSÉGUR, J. (1994). Evidence that Na<sup>+</sup>/H<sup>+</sup> exchanger isoforms NHE1 and NHE3 exist as stable dimers in membranes with a high degree of specificity for homodimers. *J. biol. Chem.* **269**, 2589–2596.
- FIÉVET, B., CLAIREAUX, G., THOMAS, S. AND MOTAIS, R. (1988). Adaptive respiratory responses of trout to acute hypoxia. III. Ion movements and pH changes in the red blood cell. *Respir. Physiol.* **74**, 99–114.
- FIÉVET, B. AND MOTAIS, R. (1991). Na<sup>+</sup>/H<sup>+</sup> exchanges and red blood cell functions in fish. In *Advances in Comparative and Environmental Physiology* (ed. R. Gilles), pp. 79–104. Heidelberg: Springer-Verlag.
- FIÉVET, B., MOTAIS, R. AND THOMAS, S. (1987). Role of adrenergic-dependent H<sup>+</sup> release from red cells in acidosis induced by hypoxia in trout. *Am. J. Physiol.* **252**, R269–R275.
- GARCIA-ROMEU, F., MOTAIS, R. AND BORGESE, F. (1988). Desensitization by external Na of the cyclic AMP-dependent Na<sup>+</sup>/H<sup>+</sup> antiporter in trout red blood cells. *J. gen. Physiol.* **91**, 529–548.
- GUIZOUARN, H., BORGESE, F., PELLISSIER, B., GARCIA-ROMEU, F. AND MOTAIS, R. (1993). Role of protein phosphorylation and dephosphorylation in activation and desensitization of the cyclic AMP-dependent Na<sup>+</sup>/H<sup>+</sup> antiport. *J. biol. Chem.* **268**, 8632–8639.
- GUIZOUARN, H., BORGESE, F., PELLISSIER, B., GARCIA-ROMEU, F. AND MOTAIS, R. (1995). Regulation of the Na<sup>+</sup>/H<sup>+</sup> exchange activity by recruitment of new Na<sup>+</sup>/H<sup>+</sup> antiporters. Effect of calyculin A, a phosphatase inhibitor. *Am. J. Physiol.* **268**, C434–C441.
- GUREVICH, V. V., CHEN, C. Y., KIM, C. M. AND BENOVIC, J. L. (1994). Visual arrestin binding to rhodopsin. Intramolecular interaction between the basic N terminus and acidic C terminus of arrestin may regulate binding selectivity. *J. biol. Chem.* **269**, 8721–8727.
- GURLAND, G. AND GUNDERSEN, G. G. (1993). Protein phosphatase inhibitors induce the selective breakdown of stable microtubules in fibroblasts and epithelial cells. *Proc. natn. Acad. Sci. U.S.A.* **90**, 8827–8831.
- HELME-KOLBE, C., MONTROSE, M. H. AND MURER, H. (1990). Parathyroid hormone regulation of Na<sup>+</sup>/H<sup>+</sup> exchange in opossum kidney cells. Polarity and mechanisms. *Pflügers Arch.* **416**, 615–623.
- HOCHULI, E., DÖBELI, H. AND SCHACHER, A. (1987). New metal chelate adsorbent selective for proteins and peptide containing neighbouring histidine residues. *J. Chromatogr.* **411**, 177–184.
- JAHNS, R., BORGESE, F., LINDENTHAL, S., STRAUB, A., MOTAIS, R. AND FIÉVET, B. (1996). Trout red cell arrestin (TRCarr), a novel member of the arrestin-family: cloning, immunoprecipitation and expression of recombinant TRCarr. *Biochem. J.* **316**, 497–506.
- KANDASAMY, R. A., YU, F. H., HARRIS, R., BOUCHER, A., HANRAHAN, J. W. AND ORLOWSKI, J. (1995). Plasma membrane Na<sup>+</sup>/H<sup>+</sup> exchanger isoforms (NHE-1, -2 and -3) are differentially responsive to second messenger agonists of the protein kinase A and C pathways. *J. biol. Chem.* **49**, 29202–29216.
- LEVINE, S., MONTROSE, M. H., TSE, C. M. AND DONOWITZ, M. (1993). Kinetics and regulation of three cloned mammalian Na<sup>+</sup>/H<sup>+</sup> exchangers stably expressed in a fibroblast cell line. *J. biol. Chem.* **268**, 25527–25535.
- LOHSE, M. J., ANDEXINGER, S., PITCHER, J., TRUKAWINSKI, S., CODINA, J., FAURE, J. P., CARON, M. G. AND LEFKOWITZ, R. J. (1992). Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of  $\beta$ -arrestin and arrestin in the  $\beta$ 2-adrenergic receptor and rhodopsin systems. *J. biol. Chem.* **267**, 8558–8564.
- LOHSE, M. J., BENOVIC, J. L., CODINA, J., CARON, M. G. AND LEFKOWITZ, R. J. (1990).  $\beta$ -Arrestin: A protein that regulates  $\beta$ -adrenergic receptor function. *Science* **248**, 1547–1549.
- MIRSHAHI, M., BORGESE, F., RAZAGHI, A., SCHEURING, U., GARCIA-ROMEU, F., FAURE, J. P. AND MOTAIS, R. (1989). Immunological detection of arrestin, a phototransduction regulatory protein, in the cytosol of nucleated erythrocytes. *FEBS Lett.* **258**, 240–243.
- MOE, O. W., AMEMIYA, M. AND YAMAJI, Y. (1995). Activation of protein kinase acutely inhibits and phosphorylates Na/H exchanger NHE-3. *J. clin. Invest.* **96**, 2187–2194.
- MOTAIS, R., SCHEURING, U., BORGESE, F. AND GARCIA-ROMEU, F. (1990). Characteristics of  $\beta$ -adrenergic-activated Na-proton transport in red blood cells. *Prog. Cell Res.* **1**, 179–193.
- NIKINMAA, M. (1982). Effects of adrenaline on red cell volume and concentration gradient of protons across the red cell membrane in the rainbow trout, *Salmo gairdneri*. *Molec. Physiol.* **2**, 287–297.
- ORLOWSKI, J., KANDASAMY, R. A. AND SHULL, G. E. (1992). Molecular cloning of putative members of the Na/H exchanger gene family. cDNA cloning, deduced amino acid sequence and mRNA tissue expression of the rat Na/H exchanger NHE-1 and two structurally related proteins. *J. biol. Chem.* **267**, 9331–9339.
- PAGÈS, G., LENORMAND, P., L'ALLEMAIN, G., CHAMBARD, J. C., MELOCHE, S. AND POUYSSÉGUR, J. (1993). Mitogen-activated protein kinases p42 mapk and p44 mapk are required for fibroblast proliferation. *Proc. natn. Acad. Sci. U.S.A.* **90**, 8319–8323.
- PARRUTI, G., PERACCHIA, F., SALLESE, M., AMBROSINI, G., MASINI, M., ROTILIO, D. AND DE BLASI, A. (1993). Molecular analysis of human  $\beta$ -arrestin-1: Cloning, tissue distribution and regulation of expression. *J. biol. Chem.* **268**, 9753–9761.
- RAPOPORT, B., KAUFMAN, K. D. AND CHAZENBALK, G. D. (1992). Cloning of a member of the arrestin family from human thyroid cDNA library. *Molec. cell. Endocr.* **84**, R39–R43.
- SARDET, C., COUNILLON, L., FRANCHI, A. AND POUYSSÉGUR, J. (1990). Growth factors induce phosphorylation of the Na<sup>+</sup>/H<sup>+</sup> antiporter, a glycoprotein of 110kD. *Science* **247**, 723–726.
- SARDET, C., FAFOURNOUX, P. AND POUYSSÉGUR, J. (1991).  $\alpha$ -Thrombin,

- epidermal growth factor and okadaic acid activate the Na<sup>+</sup>/H<sup>+</sup> exchanger, NHE-1, by phosphorylating a set of common sites. *J. biol. Chem.* **266**, 19166–19171.
- SARDET, C., FRANCHI, A. AND POUYSSÉGUR, J. (1989). Molecular cloning, primary structure and expression of the human growth factor-activable Na<sup>+</sup>/H<sup>+</sup> antiporter. *Cell* **56**, 271–280.
- SCHEURING, U., FRANCO, M., FIÉVET, B., GUIZOUARN, H., MIRSHAHI, M., FAURE, J. P. AND MOTAIS, R. (1990). Arrestin from nucleated red blood cells binds to bovine rhodopsin in a light-dependent manner. *FEBS Lett.* **276**, 192–196.
- SHINOHARA, T., DIETZSCHOLD, B., CRAFT, C., WISTOW, G. J., EARLY, J. J., DONOSO, L. A., HOROWITZ, J. AND TAO, R. (1987). Primary and secondary structure of bovine retinal S antigen (48-kDa protein). *Proc. natn. Acad. Sci. U.S.A.* **84**, 6975–6979.
- STERN-MARR, R., GUREVICH, V. V., GOLDSMITH, P., BODINE, R. C., SANDERS, C., DONOSO, L. A. AND BENOVIC, J. L. (1993). Polypeptide variants of β-arrestin and arrestin3. *J. biol. Chem.* **268**, 15640–15648.
- THOMAS, S., FIÉVET, B., CLAIREAUX, G. AND MOTAIS, R. (1988). Adaptive respiratory responses of trout to acute hypoxia. I. Effects of water ionic composition on blood acid–base status response and gill morphology. *Respir. Physiol.* **74**, 77–90.
- TSE, C. M., LEVINE, S., YUN, C. H. C., MONTROSE, M. H., LITTLE, P. J., POUYSSÉGUR, J. AND DONOWITZ, M. (1993). Cloning and expression of a rabbit cDNA encoding a serum-activated ethylisopropylamiloride-resistant epithelial Na<sup>+</sup>/H<sup>+</sup> exchanger isoform (NHE-2). *J. biol. Chem.* **268**, 11917–11924.
- WAKABAYASHI, S., BERTRAND, B., SHIGEKAWA, M., FAFOURNOUX, P. AND POUYSSÉGUR, J. (1994). Growth factor activation and ‘H<sup>+</sup>-sensing’ of the Na<sup>+</sup>/H<sup>+</sup> exchanger isoform 1 (NHE1). Evidence in favor of a regulatory ‘accessory’ factor. *J. biol. Chem.* **269**, 5583–5588.
- WAKABAYASHI, S., FAFOURNOUX, P., SARDET, C. AND POUYSSÉGUR, J. (1992). The Na<sup>+</sup>/H<sup>+</sup> antiporter cytoplasmic domain mediates growth factor signals and controls ‘H<sup>+</sup>-sensing’. *Proc. natn. Acad. Sci. U.S.A.* **89**, 2424–2428.
- WANG, Z., ORLOWSKI, J. AND SCHULL, G. E. (1993). Primary structure and functional expression of a novel gastrointestinal isoform of the rat Na/H exchanger. *J. biol. Chem.* **268**, 11925–11928.
- WILDEN, U., HALL, S. W. AND KÜHN, H. (1986). Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. *Proc. natn. Acad. Sci. U.S.A.* **83**, 1174–1178.
- YUN, C. H. C., TSE, C. M., NATH, S. K., LEVINE, S. A., BRANT, S. R. AND DONOWITZ, M. (1995). Mammalian Na<sup>+</sup>/H<sup>+</sup> exchanger gene family: structure and function studies. *Am. J. Physiol.* **269**, G1–G11.